Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

TAILORx is the first trial that has been developed as a result of the NCI’s “Program for the Assessment of Clinical Cancer Tests,” (PACCT).  The study population will include patients with estrogen-receptor (ER) positive, axillary lymph node negative breast cancer.  The Oncotype DX test being used in TAILORx is a 21 gene RT-PCR-bases assay that may be performed on routinely processed, formalin-fixed, paraffin embedded tissue.

Contact Meagan Fair at 508-595-2204 for more information.

For more information about this study: